Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Retreatment with a BTKI plus venetoclax after relapse is effective in CLL: insights from CAPTIVATE

Nitin Jain • 15 Jun 2024
EHA 2024
Chronic Lymphocytic Leukemia Leukemia Antibodies BTK inhibitors Ibrutinib Obinutuzumab Venetoclax
CAPTIVATE

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of the CAPTIVATE trial (NCT02910583), which investigated if patients with chronic lymphocytic leukemia (CLL) could be effectively retreated with a BTK inhibitor plus venetoclax after relapse. Results showed that patients who relapsed one year after treatment ended did not develop acquired resistance mutations, and they all responded when retreated with the same agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nitin Jain

2:21
Real-world experience of the use of brexu-cel in patients with B-ALL and less than 5% marrow blasts
Nitin Jain • 15 Jun 2024
1:25
Preliminary results from a Phase Ib trial of AS-1763, a novel non-covalent BTKi, in CLL/MCL
Nitin Jain • 15 Jun 2024
1:43
Results from a Phase II trial of pirtobrutinib, venetoclax, and obinutuzumab in CLL
Nitin Jain • 15 Jun 2024
1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023

Related Videos

1:13
Cytometry versus morphology in the monitoring of AML
Sanam Loghavi • 14 Jun 2024
0:51
Unmet needs in front-line therapy for patients with FLT3-mutated AML
Amir Fathi • 25 Jun 2024
2:57
The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
Anita Rijneveld • 17 Jun 2024
1:55
The ALPINE trial shows improved outcomes with zanubrutinib versus ibrutinib in R/R CLL
Jennifer Brown • 14 Jun 2024
The content of VJHemOnc is intended for healthcare professionals